Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for Clostridioides difficile Infection (MODIFY III)

BACKGROUND: Therapies to prevent recurrence of Clostridioides difficile infection (CDI) in pediatric patients are needed. Bezlotoxumab is a fully human monoclonal antibody approved for prevention of recurrent CDI in adults. We assessed the pharmacokinetics, safety, tolerability, and efficacy of bezl...

Descripción completa

Detalles Bibliográficos
Autores principales: Sferra, Thomas J, Merta, Tomas, Neely, Michael, Murta de Oliveira, Claudia, Lassaletta, Alvaro, Fortuny Guasch, Claudia, Dorr, Mary Beth, Winchell, Gregory, Su, Feng-Hsiu, Perko, Sarah, Fernsler, Doreen, Waskin, Hetty, Holden, Stephen R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312293/
https://www.ncbi.nlm.nih.gov/pubmed/37389891
http://dx.doi.org/10.1093/jpids/piad031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312293/
https://www.ncbi.nlm.nih.gov/pubmed/37389891
http://dx.doi.org/10.1093/jpids/piad031

Ejemplares similares